ClinicalTrials.gg
Active, not recruitingNCT07795606SHIELD-ETUpdated Nov 9, 2026

An Observational Study to Learn How Mirena and Other Progestogen Treatments Are Used for Endometrial Protection in Women 40+ With a Uterus in the United States Receiving Estrogen Therapy, and Their Respective Health Outcomes

An observational study in Estrogen Therapy, sponsored by Bayer. Active, not recruiting at 2 sites in United States. Open to female participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Bayer · Observational

Updated Nov 9, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
456,000
Ages
40 Years and older
Sex
Female
01

Study summary

This is an observational study in which researchers will use claims data already collected from women in the United States who received their usual care. The study will look at women aged 40 years and older who have a uterus and started estrogen therapy.

Estrogen therapy is often used to treat menopause symptoms, such as hot flashes and night sweats, or to help prevent bone loss. Women who take estrogen and still have a uterus usually also need a progestogen to help protect the lining of the uterus. Without this protection, the lining may become too thick. This can lead to endometrial hyperplasia and may increase the risk of endometrial cancer.

This study will look at how Mirena and other progestogen treatments are used in routine medical care to protect the lining of the uterus during estrogen therapy. Mirena is a small device placed in the uterus that releases the hormone levonorgestrel (a synthetic progestogen, similar to progesterone). In the United States, Mirena is approved for birth control and for treatment of heavy menstrual bleeding. Clinicians may also use it for endometrial protection during estrogen therapy. Bayer's Mirena levonorgestrel-containing intrauterine system (LNG-IUS) 52 mg is approved for endometrial protection during hormone therapy in over 100 countries outside of the US.

The main purpose of this study is gain insight into how different progestogen treatments are used in the context of estrogen therapy in women with a uterus, and the health outcomes linked with them. Researchers will describe how often women use estrogen alone, estrogen with Mirena, or estrogen with other progestogen treatments in the past 10 years. Researchers will also look at how often endometrial hyperplasia, endometrial cancer, abnormal or heavy bleeding, and hysterectomy occur in these groups over time.

The data will come from two U.S. health insurance claims databases: Optum Clinformatics Data Mart and MarketScan Commercial Claims and Encounters Database. The study period covers 2014 through 2025, depending on the database. Optum: January 2015-December 2025 and MarketScan: October 2014-September 2025, with patient identification periods of Optum: January 2016-December 2024 and MarketScan: October 2015-September 2024. Researchers will follow each participant's available data for at least 12 months before and at least 12 months after starting estrogen therapy, with follow-up of up to 10 years.

No study treatment will be given as part of this study. Researchers will only review anonymous health insurance claims data that were already collected during routine care.

02

Conditions studied

  • Estrogen Therapy
03

In context

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population for the SHIELD-ET study are patients 40+ years of age with a uterus receiving estrogen therapy. Special populations or subpopulations among menopausal women (e.g. chemotherapy- or drug-induced menopause), as well as women without a uterus will be excluded.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least one claim of estrogen therapy (ET) during the patient identification period (Index date: the first claim for ET)
  • Age ≥ 40 years at the index date
  • Patients with minimum continuous enrollment 12 months prior and 12 months at minimum after index date

Exclusion criteria

Exclusion Criteria:

  • Women without a uterus (claims of hysterectomy) in the 12-month baseline period
  • Use of any hormonal in the 12-month baseline period
  • Claims indicative of atypical endometrial hyperplasia or endometrial cancer or heavy menstrual bleeding (HMB)/abnormal uterine bleeding (AUB)/ bleeding (PMB), or any treatment for late state or endometrial cancer, in the baseline period.
  • Claims in the baseline period for any of the treatments of interest
  • Claims of chemotherapy/endocrine therapy in the baseline period
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
456,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Estrogen therapy (ET) unopposed

    Women receiving estrogen therapy (ET) alone without evidence of concomitant progestogen use during the exposure assessment period.

    Drug: Estrogen therapy

  • ET + Mirena LNG-IUS

    Women receiving estrogen therapy (ET) with recurring prescription fills and evidence of Mirena levonorgestrel-releasing intrauterine system (LNG-IUS) use, identified through a Mirena insertion procedure code and/or device code during the exposure assessment period.

    Device: Mirena levonorgestrel-releasing intrauterine system

  • ET + other progestogen

    Women receiving estrogen therapy (ET) with recurring prescription fills and evidence of concomitant progestogen use other than Mirena LNG-IUS during the exposure assessment period. Other progestogen therapies include progesterone, synthetic progestins, Liletta LNG-IUS 52 mg, and combination estrogen-progestogen products.

    Drug: Other progestogen therapy

Interventions

  • DrugEstrogen therapy

    Estrogen therapy prescribed during routine clinical practice and identified through prescription claims data. Exposure to estrogen therapy is determined using study-specific claims-based definitions.

  • DeviceMirena levonorgestrel-releasing intrauterine system

    A levonorgestrel-releasing intrauterine system used for endometrial protection in women receiving estrogen therapy. Exposure is identified through Mirena insertion procedure codes and/or device codes in claims data. Contraception use of this product is not exposure of interest and baseline hormonal contraception is an exclusion criterion.

    Also known as: Mirena LNG-IUS

  • DrugOther progestogen therapy

    rogestogen therapy used for endometrial protection in women receiving estrogen therapy, including progesterone, synthetic progestins, Liletta LNG-IUS 52 mg, and combination estrogen-progestogen products. Exposure is identified through claims data. Contraceptive use of these products is not exposure of interest, and baseline hormonal contraception is an exclusion criterion.

06

What researchers measure

Primary outcomes

  1. Proportion of patients receiving estrogen therapy

    Proportion of eligible female patients aged 40 years and older with a uterus who received at least one claim for estrogen therapy during the study period. The numerator is the number of patients with at least one estrogen therapy claim during the study period, and the denominator is the number of eligible female patients contributing at least one observable person-day during the study period.

    Time frame: Retrospective analysis from January 2025 to December 2025

  2. Number of patients by treatment subgroup within 30 and 90 days of estrogen therapy initiation

    Number of patients in each treatment subgroup (ET unopposed, ET + Mirena LNG-IUS, and ET + other progestogen) within 30 and 90 days after initiation of estrogen therapy.

    Time frame: Within 30 days and 90 days after estrogen therapy initiation during the study period (January 2025 to December 2025)

  3. Proportion of patients by treatment subgroup within 30 and 90 days of estrogen therapy initiation

    Proportion of patients in each treatment subgroup (ET unopposed, ET + Mirena LNG-IUS, and ET + other progestogen) within 30 and 90 days after initiation of estrogen therapy.

    Time frame: Within 30 days and 90 days after estrogen therapy initiation during the study period (January 2025 to December 2025)

  4. Average length of estrogen therapy use

    The average length of estrogen therapy (ET) use will be expressed as the mean duration (in days) among all eligible patients. The length of ET use will be measured as the time from the first ET prescription date to the last ET prescription date, with a maximum allowable gap of 30 days between consecutive prescriptions to be considered continuous therapy.

    Time frame: Retrospective analysis from January 2025 to December 2025

Secondary outcomes

  1. Overall (10-year) incidence of atypical, non-atypical and unspecified endometrial hyperplasia, endometrial cancer, abnormal/unscheduled/heavy menstrual bleeding and hysterectomy

    Overall incidence of atypical, non-atypical, and unspecified endometrial hyperplasia, endometrial cancer, abnormal/unscheduled/heavy menstrual bleeding, and hysterectomy among patients in each treatment subgroup (ET unopposed, ET + Mirena LNG-IUS, and ET + other progestogen). Overall incidence will be evaluated over the 10-year study period. For each outcome, incident cases are defined as patients with at least one new claim for the condition of interest during follow-up. Only the first occurrence of each outcome after the index date will be counted as an incident event. Outcomes are assessed after completion of the 30- and 90-day exposure assessment periods, and only first incident events during follow-up are counted.

    Time frame: Retrospective analysis from January 2016 to December 2025

  2. Annual incidence of atypical, non-atypical and unspecified endometrial hyperplasia, endometrial cancer, abnormal/unscheduled/heavy menstrual bleeding and hysterectomy

    Annual incidence of atypical, non-atypical, and unspecified endometrial hyperplasia, endometrial cancer, abnormal/unscheduled/heavy menstrual bleeding, and hysterectomy among patients in each treatment subgroup (ET unopposed, ET + Mirena LNG-IUS, and ET + other progestogen). For each outcome, incident cases are defined as patients with at least one new claim for the condition of interest during follow-up. Patients will be counted only in the calendar year of their first occurrence for each outcome.

    Time frame: Annually from January 2016 through December 2025

  3. Participant demographic characteristics: age

    Time frame: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])

  4. Participant demographic characteristics: race

    Time frame: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])

  5. Participant demographic characteristics: ethnicity

    Time frame: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])

  6. Participant demographic characteristics: region

    Time frame: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])

  7. Participant demographic characteristics: health plan type

    Time frame: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])

  8. Gynecologic history: endometrial polyps, fibroids, adenomyosis, endometriosis

    Time frame: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])

  9. Clinical characteristics: relevant comorbidities

    Time frame: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])

  10. Clinical characteristics: Charlson Comorbidity Index (CCI)

    The CCI is a method of estimating the one-year mortality for a patient with certain comorbid conditions. Each comorbid condition is given a score of 1, 2, 3 or 6 based on the degree of mortality attributed to the condition. The scores are summed to yield a total index score which can be used to predict long-term survival. Higher scores indicate a greater comorbidity burden and a higher predicted risk of mortality.

    Time frame: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])

  11. Proportion of patients with a diagnosis of menopause

    Time frame: At baseline (within 12 months before the first estrogen therapy prescription claim [index date])

07

Study locations

2 sites
  • Mirative MarketScan Commercial Claims and Encounters Database
    Ann Arbor, Michigan 48108, United States
  • Optum Clinformatics™ Data Mart (CDM)
    Eden Prairie, Minnesota 55344, United States
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Aug 2026 (actual). Primary completion is estimated for Jan 2027, 5 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Oct 2026 → Jan 2027 and completion Dec 2026 → Jan 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2026
First posted
Aug 31, 2026
StartActual
Aug 31, 2026
Primary completionEst.
Jan 31, 2027was Oct 2026
CompletionEst.
Jan 31, 2027was Dec 2026
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Active, not recruiting
changed Oct 19, 2026
Primary completion
Oct 30, 2026→Jan 31, 2027
Nov 9, 2026
Study completion
Dec 31, 2026→Jan 31, 2027
Nov 9, 2026
Show all 2 updates
  1. Nov 9, 2026
    Primary completion Oct 30, 2026→Jan 31, 2027
    Study completion Dec 31, 2026→Jan 31, 2027
    + 1 other change: verification date
  2. Oct 19, 2026
    Not yet recruiting→Active, not recruiting
    + 3 other changes: verification date, date precision and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07795606
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Aug 31, 2026
Start date
Aug 31, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
Nov 9, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion